Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)
一项 2 期开放标签试验 (ATLAS) 评估了 rucaparib 对既往接受过治疗的局部晚期或转移性尿路上皮癌患者的疗效和安全性。
期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-021-08085-z
Grivas, P; Loriot, Y; Morales-Barrera, R; Teo, M Y; Zakharia, Y; Feyerabend, S; Vogelzang, N J; Grande, E; Adra, N; Alva, A; Necchi, A; Rodriguez-Vida, A; Gupta, S; Josephs, D H; Srinivas, S; Wride, K; Thomas, D; Simmons, A; Loehr, A; Dusek, R L; Nepert, D; Chowdhury, S